Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

   Completed · Phase 3 · Atrial Fibrillation

   NCT00174785 · Sanofi-aventis U.S. LLC · 0 U.S. investigators

   $1,250research payments

2. A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

   Terminated · Phase 2 · Pleural Mesothelioma

   NCT04914897 · Sanofi US Services Inc. · 1 U.S. investigator

   $1,250research payments

3. Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

   Completed · Phase 2 · Idiopathic Pulmonary Fibrosis

   NCT05130970 · Csl Behring · 1 U.S. investigator

   $1,250research payments

4. GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms

   Completed · Not applicable · Thoracoabdominal Aortic Aneurysm

   NCT02528500 · W. L. Gore & Associates, Inc. · 1 U.S. investigator

   $1,230research payments

5. A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

   Completed · Phase 1 · Healthy Volunteer

   NCT07141199 · AbbVie Inc. · 0 U.S. investigators

   $1,210research payments

6. Early Internal Fixation Versus NonOperative Care With Early Rehabilitation for LC1 Fragility Fractures of the Pelvis

   Suspended · Not applicable · Multiple Closed Pelvic Fractures With Disruption of Pelvic Ring

   NCT06496867 · Teleflex LLC · 1 U.S. investigator

   $1,200research payments

7. MASTERMIND-Pneumonia Study (Also Known as Pneumonia Direct Pilot)

   Completed · Pneumonia, Bacterial

   NCT06181669 · Biofire Diagnostics, LLC · 1 U.S. investigator

   $1,174research payments

8. A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

   Recruiting · Systemic Lupus Erythematosus (SLE)

   NCT07175285 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

   $1,169research payments

9. A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

   Active, not recruiting · Phase 1, Phase 2 · Advanced Solid Tumors

   NCT06730750 · E.r. Squibb & Sons, L.l.c. · 2 U.S. investigators

   $1,139research payments

10. A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily

    Completed · Phase 3 · Presbyopia

    NCT04983589 · AbbVie Inc. · 1 U.S. investigator

    $1,070research payments

11. A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

    Recruiting · Phase 3 · Palmoplantar Pustulosis

    NCT07219420 · UCB SA · 1 U.S. investigator

    $1,063research payments

12. Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation

    Completed · Not applicable · Paroxysmal Atrial Fibrillation

    NCT04580914 · Boston Scientific Corporation · 2 U.S. investigators

    $1,000research payments

13. Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

    Terminated · Phase 2 · Cystic Fibrosis (CF)

    NCT04853368 · AbbVie Inc. · 1 U.S. investigator

    $1,000research payments

14. A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

    Completed · Phase 3 · Multiple Myeloma

    NCT02181413 · Takeda Pharmaceuticals U.S.A., Inc. · 1 U.S. investigator

    $985research payments

15. Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

    Recruiting · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment

    NCT04846959 · AbbVie Inc. · 9 U.S. investigators

    $950research payments

16. A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

    Completed · Phase 3 · Non-Small Cell Lung Cancer (NSCLC)

    NCT04026412 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $935research payments

17. A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

    Completed · Phase 3 · SARS-CoV-2

    NCT04470427 · ModernaTX, Inc. · 1 U.S. investigator

    $922research payments

18. A Study of LY3561774 in Participants With Mixed Dyslipidemia

    Completed · Phase 2 · Dyslipidemias

    NCT05256654 · Eli Lilly and Company · 1 U.S. investigator

    $920research payments

19. A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

    Recruiting · Phase 1, Phase 2 · Lung Cancer

    NCT06618287 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $913research payments

20. A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

    Completed · Phase 3 · Atopic Dermatitis

    NCT03738397 · AbbVie Inc. · 1 U.S. investigator

    $875research payments

21. A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

    Completed · Phase 3 · Acute Myeloid Leukemia (AML)

    NCT03941964 · AbbVie Inc. · 1 U.S. investigator

    $875research payments

22. Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin

    Completed · Phase 1 · Drug-drug Interaction

    NCT05306379 · Aurinia Pharma U.S., Inc. · 1 U.S. investigator

    $824research payments

23. A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

    Active, not recruiting · Phase 1 · Advanced Solid Tumor

    NCT05259709 · Regeneron Pharmaceuticals, Inc. · 0 U.S. investigators

    $765research payments

24. Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

    Completed · Phase 3 · Atopic Dermatitis

    NCT02260986 · Genzyme Corporation · 0 U.S. investigators

    $750research payments

25. Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

    Completed · Phase 3 · Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

    NCT02898454 · Genzyme Corporation · 0 U.S. investigators

    $750research payments

26. A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

    Completed · Phase 2 · Diabetic Gastroparesis

    NCT03544229 · Takeda Pharmaceuticals U.S.A., Inc. · 1 U.S. investigator

    $750research payments

27. Building Self-regulation Capacity in AA T2DM Women: Feasibility of EMI

    Terminated · Not applicable · Type 2 Diabetes

    NCT04083248 · Ipsen Bioscience Inc. · 1 U.S. investigator

    $750research payments

28. Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

    Terminated · Phase 1 · Upper Limb Spasticity

    NCT05956509 · AbbVie Inc. · 1 U.S. investigator

    $750research payments

29. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants

    Completed · Phase 1 · Healthy Volunteers

    NCT07136103 · AbbVie Inc. · 0 U.S. investigators

    $720research payments

30. A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform

    Completed · Not applicable · Osteoarthritis, Knee

    NCT03737149 · Zimmer Biomet Holdings, Inc. · 2 U.S. investigators

    $708research payments

31. A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

    Recruiting · Phase 1 · Lymphoma, Non-Hodgkin

    NCT07101328 · Eli Lilly and Company · 0 U.S. investigators

    $550research payments

32. Effect of Efpeglenatide on Cardiovascular Outcomes

    Terminated · Phase 3 · Type 2 Diabetes Mellitus

    NCT03496298 · Sanofi US Services Inc. · 1 U.S. investigator

    $514research payments

33. A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

    Recruiting · Phase 3 · Extensive-Stage Small Cell Lung Cancer

    NCT06646276 · E.r. Squibb & Sons, L.l.c. · 2 U.S. investigators

    $513research payments

34. Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

    Terminated · Phase 3 · Ulcerative Colitis

    NCT03259334 · Takeda Pharmaceuticals U.S.A., Inc. · 1 U.S. investigator

    $507research payments

35. A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

    Terminated · Phase 3 · Cardiomyopathy, Hypertrophic

    NCT05582395 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $502research payments

36. Safety and Efficacy of the Vibrant Soundbridge (VSB) for Mixed and Conductive Hearing Losses

    Completed · Not applicable · Hearing Loss

    NCT00748540 · Med-el Corporation · 1 U.S. investigator

    $500research payments

37. A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy

    Enrolling by invitation · Pregnancy

    NCT05872022 · Novo Nordisk As · 2 U.S. investigators

    $500research payments

38. A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

    Active, not recruiting · Phase 3 · Non Squamous Non Small Cell Lung Cancer

    NCT06939595 · Celltrion, Inc. · 0 U.S. investigators

    $490research payments

39. A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

    Completed · Phase 3 · Type 2 Diabetes Mellitus

    NCT03882970 · Eli Lilly and Company · 1 U.S. investigator

    $473research payments

40. VCLIP Post-Market Study, Long-term Follow-up on LAA Exclusion Using AtriClip

    Completed · Not applicable · Left Atrial Appendage Absent

    NCT05101993 · Atricure, Inc. · 1 U.S. investigator

    $435research payments

41. A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

    Completed · Phase 3 · Type 2 Diabetes

    NCT04537923 · Eli Lilly and Company · 1 U.S. investigator

    $425research payments

42. A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes

    Completed · Phase 3 · Type 2 Diabetes

    NCT06010004 · Eli Lilly and Company · 4 U.S. investigators

    $396research payments

43. An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

    Completed · Phase 1, Phase 2 · Hepatocellular Carcinoma

    NCT01658878 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $385research payments

44. The Savella Pregnancy Registry

    Terminated · Fibromyalgia

    NCT01026077 · AbbVie Inc. · 0 U.S. investigators

    $363research payments

45. Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

    Completed · Phase 1 · Healthy Volunteers

    NCT05732194 · Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) · 1 U.S. investigator

    $338research payments

46. An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread

    Completed · Phase 2 · Cancer

    NCT02832167 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $290research payments

47. Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

    Completed · Phase 2 · Obesity

    NCT05616013 · Eli Lilly and Company · 3 U.S. investigators

    $281research payments

48. A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

    Completed · Phase 2, Phase 3 · Ulcerative Colitis (UC)

    NCT03398148 · AbbVie Inc. · 1 U.S. investigator

    $250research payments

49. A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

    Completed · Phase 1 · Healthy Participants

    NCT07020988 · UCB SA · 0 U.S. investigators

    $247research payments

50. A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

    Active, not recruiting · Phase 1 · Advanced Solid Tumors Cancer

    NCT02988960 · AbbVie Inc. · 1 U.S. investigator

    $239research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.